SEC Form 4

Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

	ANI PHARMACEUTICALS INC [ANIP] (Check all applicable) X Director 10% Owner X Officer (give title Other (specify below) HEAD OF R&D, COO-NOVITIUM OPS 4. If Amendment, Date of Original Filed (Month/Day/Year) AUDETTE MN 56623 ANI PHARMACEUTICALS, INC. ANIPHARMACEUTICALS, I										
1. Nume and Address of Reporting Ferson											
<u>Snanmugam wutnusamy</u>				X	Director	10% Owner					
(Last) C/O ANI PHA	. ,	()			below)	below)					
210 MAIN STREET WEST			4. If Amendment, Date of Original Filed (Month/Day/Year)								
(Street)				X	Form filed by One Rep	orting Person					
BAUDETTE	MN	56623			· ·	n One Reporting					
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication								
			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to								

Χ satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securities Disposed Of			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock								47,407	D	
Common Stock	08/14/2023		S ⁽¹⁾		27,890	D	\$61.15 ⁽²⁾	1,204,730	Ι	Held by Esjay LLC ⁽³⁾
Common Stock	08/15/2023		S ⁽¹⁾		22,110	D	\$61.6 ⁽⁴⁾	1,182,620	Ι	Held by Esjay LLC ⁽³⁾
Common Stock								5,000	I	Held by SS Pharma LLC ⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

										8					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv Secu Acqu (A) of Dispo of (D)	Derivative (Month/Day/Year) Securities A) or Disposed of (D) Instr. 3, 4		ate	7. Titl Amou Secur Unde Deriv Secur 3 and	int of rities rlying ative rity (Instr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from \$60.12 to \$62.58, inclusive.

3. The reporting person holds voting and dispositive power over the shares held by Esjay LLC.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from \$60.81 to \$62.59, inclusive.

5. The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.

Remarks:

/s/ Muthusamy Shanmugam, by attorney-in-fact Meredith 08/16/2023 W. Cook

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.